Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Checkpoint kinase 1 (Chk1)

Mouse studies identified a Chk1 inhibitor that could help treat cancer. In a transgenic mouse model of neuroblastoma, oral treatment with the lead Chk1 inhibitor, CCT244747, decreased tumor burden compared with vehicle. In a mouse xenograft model of human colon cancer, CCT244747 plus chemotherapy decreased tumor growth better than chemotherapy alone. Next steps could include optimization of the lead Chk1 inhibitor and IND-enabling studies.
At least four companies have Chk1 inhibitors in preclinical or clinical development to treat cancer.

SciBX 5(43); doi:10.1038/scibx.2012.1133
Published online Nov. 1, 2012

Patent and licensing status undisclosed

Lainchbury, M. et al. J. Med. Chem.; published online Oct. 19, 2012;
doi:10.1021/jm3012933
Contact: Ian Collins, The Institute of Cancer Research, Sutton, U.K.
e-mail:
ian.collins@icr.ac.uk